Key result
Ticagrelor significantly suppressed platelet function compared to clopidogrel, demonstrating lower maximal light transmittance changes (18.5% vs 38.8%) in Chinese patients undergoing percutaneous coronary intervention.
Why the study?
Knowledge regarding the pharmacodynamic effects of clopidogrel and ticagrelor in Asian patients is scarce.
Does ticagrelor reduce platelet reactivity compared to clopidogrel in Chinese patients undergoing percutaneous coronary intervention?
Cohort (n=112)
No
Does ticagrelor reduce platelet reactivity compared to clopidogrel in Chinese patients undergoing percutaneous coronary intervention?
Absolute Event Rate: 18.5% vs 38.8%
p-value: p=<0.001
Ticagrelor provides significantly greater platelet inhibition and a lower rate of high on-treatment platelet reactivity compared to clopidogrel in Chinese patients undergoing PCI.
Scarce pharmacodynamic data in Chinese PCI patients are addressed; MPV-HPR link remains hypothesis-generating pending validation.
Background: Knowledge on the pharmacodynamic effects of antiplatelet drugs including clopidogrel and ticagrelor on Asian patients is scarce. We aim to evaluate the effects of the two drugs on platelet reactivity in the treatment of Chinese patients who underwent percutaneous coronary intervention (PCI), using two platelet function tests (PFT). Meanwhile, the relationship between mean platelet volume (MPV), a routine index of platelet size, and high on-treatment platelet reactivity (HPR) is also investigated.Methods: Patients receiving dual antiplatelet therapy (DAPT) were scheduled for the assessment of platelet reactivity at 2–3 days after PCI. Two PFTs, light transmission aggregometry (LTA) and vasodilator-stimulated phosphoprotein (VASP)-FCM assay, were applied in the evaluation of platelet reactivity. The MPV was measured simultaneously with EDTA plasma using a Sysmex XN 2000 automated hematology analyzer.Results: The final study population included the aspirin + clopidogrel group (n = 46) and the aspirin + ticagrelor group (n = 66). In the aspirin + ticagrelor group, the maximal light transmittance (LT) changes in response to 5 µM ADP assessed by LTA was obviously lower than that in the aspirin + clopidogrel group (P < 0.001). The platelet reactivity index (PRI) level in the VASP test was also markedly lower in the group given aspirin and ticagrelor (P < 0.001). There was a significant difference in HPR between the two groups. MPV showed a potent ability to predict the presence of HPR at VASP assay (AUC = 0.788, 95% CI: 0.701–0.875, P < 0.001) in receiver-operating characteristic curve analysis.Conclusions: Compared with clopidogrel, ticagrelor has dramatically greater antiplatelet effect, with a superiority in suppressing platelet function and a lower HPR rate. In addition, there existed a significant independent association between MPV and high prevalence of HPR in the VASP assay.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2021) conducted a cohort in Percutaneous coronary intervention (PCI) (n=112). Ticagrelor vs. Clopidogrel (300 mg loading dose, 75 mg once daily maintenance) was evaluated on Maximal light transmittance (LT) changes in response to 5 µM ADP assessed by light transmission aggregometry (LTA) (p=<0.001). Ticagrelor significantly suppressed platelet function compared to clopidogrel, demonstrating lower maximal light transmittance changes (18.5% vs 38.8%) in Chinese patients undergoing percutaneous coronary intervention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: